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Introduction. The degree of liver fibrosis is of great importance for prognosis and therapeutic 
intervention in chronic liver diseases. However, there is a relative lack of tools and technologies 
for non-invasive and longitudinal assessment of liver fibrosis in autoimmune hepatitis (AIH). 
Low sensitivity and specificity of currently available diagnostic options highlight the necessity 
of fibrosis biomarker identification.  
Aim of the study. To analyze the importance of non-invasive biomarkers for liver fibrosis 
assessment in AIH.  
Materials and methods. A scientific review have been performed using HINARI database. 
Based on search terms “liver fibrosis”, “non-invasive tests” and “biomarkers”, articles on this 
topic have been identified and the most relevant ones have been studied.  
Results. The extracellular matrix (ECM) may provide options for biomarker identification, as 
both the content and the composition of the ECM correlate with fibrosis stage. The balance 
between matrix metalloproteases (MMP) and tissue inhibitors of metalloproteases (TIMP) 
affects the turnover model of ECM, thus MMP-1, MMP-3, TIMP-1 are applied in non-invasive 
diagnosis as reliable fibrosis markers. The N-terminal propeptide of procollagen type III 
(PIIINP) reveals the intensity of ECM synthesis, but its specificity and sensitivity in fibrosis 
evaluation is considerable higher if associated with hyaluronic acid and MMP. Despite their 
high applicability and good reproducibility, biomarkers present some limitations in displaying 
liver fibrosis, because they are not liver specific and unable to discriminate between 
intermediate stages of fibrosis. On the other hand, transient elastography via liver stiffness 
measurement can stage hepatic fibrosis, especially with high performance for cirrhosis. 
However, the accuracy of this non-invasive technique in AIH is still limited due to false 
positive results in conditions like acute hepatitis, extrahepatic cholestasis, liver congestion, and 
lower applicability than serum biomarkers in case of ascites or/and obesity.  
Conclusions. There is increasing evidence for the prognostic value of both functional and 
imaging biomarkers as liver fibrosis non-invasive assessment methods in AIH. Certainly, the 
combination of these different tools will overcome their individual disadvantages and allow a 
more personalized fibrosis staging.  
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Introduction. Oxidative stress is a pathogenic mechanism of a number of diseases that affect 
tissues and organs. The usefulness of the blood markers in the diagnosis of the diseases and/or 
conditions associated with oxidative stress is substantiated by the blood expression of oxidative 
stress and the correlation with the intensity of the pathological process in the organs. An 
indirect marker for oxidative stress is malonic dialdehyde (DAM), the end product of lipid 
peroxidation triggered by oxidative stress. The assessment of the DAM level could reveal the 
intensity of the processes and can determine the therapeutic strategy.   
Aim of the study. To assess the level of DAM in the blood and the hepatic homogenate of 
laboratory animals in oxidative stress induced by muscle ischemia/reperfusion in crush 
syndrome.  
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Materials and methods. The DAM level was measured by the classical thiobarbituric acid 
method, described by Vladimirov Iu. (1972), in the hepatic homogenate and erythrocytes of 
white laboratory rats subjected to muscle ischemia (240 min) and reperfusion (90 min) 
compared to control (240 min. ischemia) and healthy animals.  
Results. Prolonged ischemia (240 min) induced an insignificant (p> 0.05) increase in the level 
of DAM in both the hepatic homogenate (+7%) and in the erythrocyte hemolysate (+9%) in 
the experimental animals compared to the healthy ones. Removal of the causal factor and 
reperfusion (90 min) of the compressed muscle tissue did not change the DAM values in the 
hepatic homogenate, but produced a statistically significant decrease, up to values below those 
found in the control animals, in erythrocytes (-25%, p<0.01). Thus, long-lasting ischemia is 
associated with an insignificant increase in the end product of lipid peroxidation, which 
possible confirms the sufficient antioxidant capacity of the liver and erythrocytes, which in the 
case of blood cells is surpassed by the oxidative explosion conditioned by the reperfusion and 
the entry of oxygen.   
Conclusions. Statistically insignificant changes of DAM content in the liver and erythrocytes 
of animals with oxidative stress triggered by ischemia/reperfusion attest minor value of DAM 
as a marker of oxidative stress at late stages of the pathological process.  
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Introduction. Hepatic fibrosis is a worldwide health issue, whose prognosis; management and 
potential treatment depend on establishing the accurate diagnosis according to the progression 
of the disease. Modern medicine studies efficient, safe and non-invasive methods for the 
assessment of hepatic fibrosis, such as serum biomarkers and imaging techniques: FibroScan 
elastometry, MRI, ARFI.  
Aim of the study. Identification and study of the non-invasive methods for the diagnosis of 
hepatic fibrosis  
Materials and methods. A bibliographic study of scientific literature from 2009-2020 based 
on Biomed Central, Bio Predictive, ACS Publications data bases was done, with the following 
search words – hepatic fibrosis, non-invasive diagnosis, fibrotest, biomarker of fibrosis.  
Results. Serum biomarkers, used for the assessment of hepatic fibrosis, are classified in: direct 
biomarkers – Procollagen type I carboxy-terminal peptide (PICP), Procollagen type III amino-
terminal peptide (PIIINP), matrix metalloproteinases (MMPs), tissue inhibitors of matrix 
metalloproteinases (TIMPs), hyaluronic acid (HA), transforming growth factor β1 (TGFβ1), 
laminin, connective tissue growth factor (CTGF); and indirect biomarkers – AST/ALT ratio, 
coagulation factors, platelet count, γ2-macroglobulin, γ2-globulin, γ-globulin, apolipoprotein 
A1, GGT, total bilirubin. These serum biomarkers are combined in non-invasive scores such 
as APRI, FibroTest, FIB-4. Transient Ultrasound Elastography or FibroScan measures liver 
stiffness (elasticity) and allows determining the stage of hepatic fibrosis according to 
METAVIR score: F1, F2, F3, and F4. MRI can be used to measure hepatic stiffness, and at the 
same time other associated pathologies.  
